The pharma giant set on Wednesday once it receives an emergency use authorization from the Food and Drug Administration, it will start delivering 300,000 doses of the treatment within two months.

The U.

S government will pay $375 million for that first delivery after that, U.

S Department of Health and Human Services said the government has an option to buy an additional 650,000 vials for more than $800 million.

Three agreement with the US came days after the company said the drug failed to show benefits in hospitalized patients.

But Eli Lilly said it remains confident it's treatment can prevent the progression of disease when it has started earlier.

There are also questions about the company's facilities.

Reuters reported that U.

S drug inspectors uncovered serious quality control problems at an Eli Lilly plant that is ramping up to make its anti body therapy.

The drugmaker said the issues raised by US regulators after the inspection do not affect the quality or safety of the treatment.

Eli Lilly applied for an FDA emergency use authorization of the drug to treat mild to moderate Koven 19 patients earlier this month.